key: cord-0992345-m9zqvs8i
authors: Parisi, Simone; Borrelli, Richard; Bianchi, Sabina; Fusaro, Enrico
title: Viral arthritis and COVID-19
date: 2020-10-05
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30348-9
sha: 2c4fe1741f9e846f577876e4803c215e713a7615
doc_id: 992345
cord_uid: m9zqvs8i

nan

The current outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is characterised by clinical signs and symptoms such as interstitial pneumonia, fatigue, and headache. 1 Arthralgia is one of the symptoms that occurs in patients with COVID-19, and is present in 14·9% of cases. 1 3 Ambient respiratory viral infections have been associated with an increased number of cases of rheumatoid arthritis (especially in women and older patients), sug gesting that respiratory viral infections might be an environmental risk factor for the development of rheumatoid arthritis. 4 SARS-CoV-2 enters the cell via the angiotensinconverting enzyme-2 (ACE-2) and it is sensed by Toll-like receptor-7 (TLR7); bioinformatic analyses have shown that the SARS-CoV-2 genome contains a large number of fragments that are recognised by TLR7. In addition to its expression in immunological cells, TLR7 is expressed predominantly in the lung and bronchus, thus allowing SARS-CoV-2 to be highly recognised in the regions of its tropism. TLR7 activation leads to activation of c-Jun N-terminal kinase and nuclear factor-κB signaling, thus leading to the production of IL-6 and IL-12p40. 5 Therefore, it is conceivable that patients with COVID-19 might display symptoms and signs of inflammation, such as a viral arthritis. 6 Thus, from the point of view of a rheumatologist, evaluating the role of SARS-CoV-2 in inflammatory arthritis is essential for diagnosis.

Serological tests could be useful to establish a diagnosis, but the possibility that low-titre positivity for autoantibodies (such as rheumatoid factor [RF] or antinuclear antibody [ANA]) could be detected in viral arthritis must also be taken into account. 7 A detailed analysis of epidemiological, clinical, and serological characteristics is required to help physi cians diagnose viral arthritis; oligoarticular or polyarticular involve ment (either symmetric or asymmetric), good response to NSAIDs, a clinical manifestation characterised by an early onset (within the first weeks of symptomatic infection) and a self-limiting presence are the elements that orientate toward a viral arthritis (appendix p 1).

We would like to share the case of a white woman, aged 58 years, who had a non-severe manifestation of COVID-19, and was treated with only paracetamol. The patient was tested for SARS-CoV-2 with qRT-PCR nasal swabs when admitted to hospital. 25 days after her pro drome of infection (arthralgia, fever, cough, nausea, diarrhoea, and dysgeusia), an ankle arthritis occurred; laboratory tests showed a slight increase in C-reactive protein (7·36 mg/L, normal range 0-5), relative lymphopenia (1·29 cells per 10⁹/L, normal range 0·76-4·80; 12·5%, normal range 19-48), and normal liver and kidney function. ANA, antiextractable nuclear antigen, antidouble-strand DNA, RF, and anticyclic citrullinated peptide antibodies were negative. Additionally, testing for human leukocyte antigen-B27 was done to exclude predisposing factors, given it is strongly associated with spondyloarthropathies. On ultrasound, a synovial hypertrophy was detected in the tibiotarsal anterior and lateral recess with power Doppler signal score of 2 (according to OMERACT score). No signs of tenosynovitis emerged in the anterior and posterior compartments exam ined, but there was evidence of tendonitis of the Achilles tendon (appendix p 1). This manifestation showed a good response to NSAIDs (ibuprofen 600 mg twice a day). The nasopharyngeal swab was negative for SARS-CoV-2 30 days after the first symptoms. For confirmation, a second nasopharyngeal swab was taken 7 days after the last negative one. The initial symptoms of fever, cough, nausea, diarrhoea, and dysgeusia improved progressively until they resolved completely within 30 days. In par ticular, the fever (between 38°C and 39°C) and cough lasted about 10 days, the nausea and diarrhoea about 3-4 days, and dysgeusia about 20 days. The arthralgia resolved after ibuprofen, but the ultra sound examination remained stable after 30 days from pharmacological treatment, and synovitis (indicated by a power Doppler signal) was still present, even in the absence of pain. To date, the patient continues to be in rheumatological follow-up.

To our knowledge, this is the first case of arthritis in a COVID-19 patient in Europe; to date, cases of arthralgia have only been reported in China 1 and a single case of arthritis was reported in Thailand. 8 Further studies are necessary to understand the pathogenesis of COVID-19 and its different clinical phenotypes, because it is important to recognise its correlation with arthritis by analysing the presence of both the virus and the antibodies in the synovial tissue; the incidence and evolution of inflammatory manifestations should be investigated as well. 

Clinical characteristics of coronavirus disease 2019 in China

Diagnosing acute monoarthritis in adults: a practical approach for the family physician

Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study

Respiratory viral infections and the risk of rheumatoid arthritis

SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv (preprint) 2020

Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes

Viral arthritis

Arthralgia as an initial presentation of COVID-19: observation